When modified using a process known as epoxidation, two naturally occurring lipids are converted into potent agents that target multiple cannabinoid receptors in neurons, interrupting pathways that promote pain and inflammation, researchers report. These modified compounds, called epo-NA5HT and epo-NADA, have much more powerful effects than the molecules from which they are derived, which also regulate pain and inflammation.
Reported in the journal Nature
Communications, the study opens a new avenue of research in the
effort to find alternatives to potentially addictive opioid pain killers,
researchers say.
The work is part of a
long-term effort to understand the potentially therapeutic byproducts of lipid
metabolism, a largely neglected area of research, said University of Illinois
Urbana-Champaign comparative biosciences professor Aditi Das,
who led the study. While many people appreciate the role of dietary lipids such
as omega-3 and omega-6 fatty acids in promoting health, the body converts these
fat-based nutrients into other forms, some of which also play a role in the
healthy function of cells, tissues and organ systems.
“Our bodies use a lot of
genes for lipid metabolism, and people don’t know what these lipids do,” said
Das, also an affiliate of the Beckman Institute for Advanced Science and
Technology and of the Cancer Center at Illinois. “When we consume
things like polyunsaturated fatty acids, within a few hours they are
transformed into lipid metabolites in the body.”
Scientists tend to think of
these molecules as metabolic byproducts, “but the body is using them for
signaling processes,” Das said. “I want to know the identity of those
metabolites and figure out what they are doing.”
She and her colleagues
focused on the endocannabinoid system, as cannabinoid receptors on cells
throughout the body play a role in regulating pain. When activated, cannabinoid
receptors 1 and 2 tend to reduce pain and inflammation, while a third receptor,
TRPV1, promotes the sensation of pain and contributes to inflammation. These
receptors work together to modulate the body’s responses to injury or disease.
“Understanding pain
regulation in the body is important because we know we have an opioid crisis,”
Das said. “We’re looking for lipid-based alternatives to opioids that can
interact with the cannabinoid receptors and in the future be used to design
therapeutics to reduce pain.”
Previous research identified
two lipid molecules, known as NA5HT and NADA, that naturally suppress pain and
inflammation. Das and her colleagues discovered that brain cells possess the
molecular machinery to epoxidize NA5HT and NADA, converting them to epo-NA5HT
and epo-NADA. Further experiments revealed that these two epoxidated lipids are
many times more potent than the precursor molecules in their interactions with
the cannabinoid receptors.
“For example, we found that
epo-NA5HT is a 30-fold stronger antagonist of TRPVI than NA5HT and displays a
significantly stronger inhibition of TRPV1-mediated responses in neurons,” Das
said. It inhibits pathways associated with pain and inflammation, and promotes
anti-inflammatory pathways.
The team was unable to
determine whether neurons naturally epoxidate NA5HT and NADA in the brain, but
the findings hold promise for the future development of lipid compounds that
can combat pain and inflammation without the dangerous side effects associated
with opioids, Das said.
Source: https://news.illinois.edu/view/6367
Journal article: https://www.nature.com/articles/s41467-021-20946-6
No comments:
Post a Comment